About Cellecta
Cellecta is a Healthcare company based in United States founded in 2006 by Alex Chenchik. It operates as a provider of RNAi and CRISPR screening products and services. Its website cellecta.com draws about 17 thousand monthly visits. Cellecta offers products and services including CRISPR Knockout Libraries, Custom Cas9 Cell Line Service, RNAi shRNA Libraries, and NGS Analysis Services. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its legal entity is CELLECTA, INC. Its competitors include Beam Therapeutics, eGenesis, Korro Bio, Metagenomi and Prime Medicine and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Cellecta was founded in 2006 in the United States as a provider of RNAi and CRISPR screening products and services. These offerings support the characterization of therapeutic targets and drugs, along with the identification of mechanisms of action. Technology utilized includes expressed barcode libraries integrated with next-generation sequencing to track clonal variations in biological studies. Operations focus on genomic research tools for academic and industry applications.
- Headquarters United States
- Founders Alex Chenchik
- SectorsHealthcare
- Website cellecta.com
- Social LinkedIn X Facebook YouTube
- Legal Name Cellecta, Inc.
- Latest Funding Round$1.72M (USD), Grant
Jun 2015
- Investors
Products & Services of Cellecta
Cellecta offers a comprehensive portfolio of products and services, including CRISPR Knockout Libraries, Custom Cas9 Cell Line Service, RNAi shRNA Libraries, and NGS Analysis Services.
Pooled lentiviral sgRNA libraries for gene knockout in research.
Service for creating and validating custom Cas9 cell lines.
Knockdown libraries for gene silencing applications.
Services for next-generation sequencing data analysis.
Apps and channels of Cellecta
its YouTube channel Cellecta has 310 subscribers and 30 videos.
Videos from Cellecta
The most watched videos on Cellecta's YouTube channel, Cellecta (310 subscribers). Click a video to play it here.
More on Cellecta.
Funding Insights of Cellecta
- Total Rounds 15
- Last Round Grant — $1.72M
- First Round $1.8M
(Aug 2006)
- Investors Count 1
Latest 10 of 15 funding rounds of Cellecta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2015 | $1.72M | Grant | – | – | |
| Aug 2011 | $1.85M | Grant | – | – | |
| Sep 2010 | $1.86M | Grant | – | – | |
| Jun 2010 | $600,000 | Grant | – | – | |
| May 2010 | $600,000 | Grant | – | – | |
| Aug 2009 | $187,669 | Grant | – | – | |
| Jul 2009 | $1.8M | Grant | – | – | |
| Jul 2009 | $2.57M | Grant | – | – | |
| Jun 2009 | $234,168 | Grant | – | – | |
| Sep 2008 | $187,669 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Cellecta
Cellecta has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Cellecta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cellecta
9 people are tracked at Cellecta (6 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Alex Chenchik | Founder & President | Leadership |
Paul Diehl | Chief Operating Officer, Director Of Business Development | Leadership |
Ruth Mercado | Marketing Director | Leadership |
Lester Kobzik | Chief Medical Officer | Leadership |
Nathan Bach | Director Of Business Development | Leadership |
Karim Hyder | Director Of Operations | Leadership |
Sonja Pinck | Digital Marketing Coordinator | Team |
Tanuka Bhattacharjee | Technical Sales Specialist | Team |
Mark Gebhard | Production Manager | Team |
Complete people profiles for Cellecta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cellecta
3 dated milestones of Cellecta across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Cellecta is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Grant, of $1.7M.
Competitors of Cellecta
Cellecta has 9 listed competitors in our database, 9 of them funded. They include Beam Therapeutics, eGenesis, Korro Bio, Metagenomi and Prime Medicine, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beamtx.com | 2017 | Cambridge, United States | $222M | 340 | Developer of gene therapy using CRISPR base editing to treat diseases | |
| egenesisbio.com | 2015 | Cambridge, United States | $481.42M | 94 | Gene transplantation platform for humanizing pig cells is developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| metagenomi.co | 2016 | Berkeley, United States | $376.37M | – | Next-generation gene editing tools are developed for drug enhancement. | |
| primemedicine.com | 2019 | Cambridge, United States | $200M | 214 | Genetic therapies for diseases are developed using prime editing technology. | |
| scribetx.com | 2018 | Alameda, United States | $120M | – | A CRISPR-based gene-editing platform is developed for therapeutic applications. | |
| eligo.bio | 2014 | Paris, France | $52.26M | – | In vivo gene editing technology is developed for microbiome modulation. | |
| tesseratherapeutics.com | 2017 | Cambridge, United States | $610M | 149 | New genome engineering technology is provided for treating multiple diseases. | |
| locus-bio.com | 2015 | Raleigh, United States | $67.33M | 74 | Developer of therapeutics for infectious disease and inflammatory indications |
Detailed competitors of Cellecta
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cellecta
The website of Cellecta (cellecta.com) receives about 16.5K visits a month.
- Monthly visits16.5K
▲ 7.3% vs previous month
Websites whose visitors overlap most with Cellecta. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bpsbioscience.com | 100% | – | #779,448 | View details | |
creative-biogene.com | creative-biogene.com | 90% | – | #888,012 | – |
| horizondiscovery.com | 86% | 63.5K | #524,580 | View details | |
bfg.oxfordjournals.org | bfg.oxfordjournals.org | 86% | – | – | – |
goldbio.com | goldbio.com | 85% | – | #237,391 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 32 similar websites and full traffic analytics for Cellecta
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 32 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Cellecta (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cellecta
Complete news archive for Cellecta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellecta
Cellecta was founded in 2006.
Cellecta is headquartered in United States.
Cellecta was founded in 2006 in the United States as a provider of RNAi and CRISPR screening products and services. These offerings support the characterization of therapeutic targets and drugs, along with the identification of mechanisms of action. Technology utilized includes expressed barcode libraries integrated with next-generation sequencing to track clonal variations in biological studies. Operations focus on genomic research tools for academic and industry applications.
Cellecta's top competitors include eGenesis, Tessera Therapeutics and Korro Bio.
Cellecta offers CRISPR Knockout Libraries, Custom Cas9 Cell Line Service, RNAi shRNA Libraries, and NGS Analysis Services.
Cellecta has 1 investor. Key investors include HHS.
Cellecta operates through Cellecta, Inc..